Egyptian Drug Authority (EDA) head Ali El-Ghamrawy met with Ahmed Hamdan Aljedai, CEO of Saudi Arabia's Spimaco Pharmaceutical, to discuss partnership with leading regional firms to support Egypt's local manufacture strategy, the Cabinet has said. The meeting aimed to discuss Spimaco's plans for industrial expansion in the Egyptian market and increasing its investments, in a way that helps meet local market needs and opens up new export opportunities. The meeting reviewed the steps to operate Spimaco Egypt's pharmaceutical manufacturing plant and affirmed the company's commitment to converting the licences of registered products from imported to locally manufactured. This move aims to enhance the value of local production and reduce the import bill. Ghamrawi highlighted the importance of continuing to adopt flexible regulatory policies that encourage global companies to inject more investments into Egypt. This would help improve the quality and availability of innovative medicines and meet patients' needs in line with the highest international standards. Dr Ahmed Hamdan Al-Jediah, CEO of Spimaco Pharmaceutical Company in Saudi Arabia, affirmed the company's commitment to boosting its investments in the Egyptian market. He noted that Egypt possesses significant capabilities that qualify it to become a regional hub for pharmaceutical manufacturing and export. He added that Spimaco is committed to actively contributing to the localisation of the pharmaceutical industry through local manufacturing at its plant in Egypt, while maintaining the highest global quality standards to meet patients' needs and support the national economy. Attribution: Amwal Al Ghad English Subediting: M. S. Salama
